These findings highlight the potential therapeutic value of targeting KIAA1429 to restore gefitinib sensitivity in resistant tumors, improve treatment outcomes for NSCLC patients and delay disease progression. The gene discussed is VIRMA; the disease is non-small cell lung carcinoma.